HIMS - Hims & Hers surges on cheap compounded versions of Novo Nordisk's semaglutide
2024-05-20 10:15:35 ET
More on Hims & Hers Health
- 10 Solid Reasons To Buy Hims & Hers Stock
- Hims & Hers: Strong Operating Leverage And Profitability Inflection
- Hims & Hers: The Growth Story, Coupled With Expanding Profitability, Promises Exponential Gains
- Hims & Hers surges 11% as 2024 revenue outlook raised, Q1 beats
- Hims & Hers Health GAAP EPS of $0.05 beats by $0.04, revenue of $278.2M beats by $9.46M